NVLN - Novelion Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6871
-0.0029 (-0.42%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.6900
Open0.6800
Bid0.0000 x 800
Ask0.8750 x 800
Day's Range0.6502 - 0.6950
52 Week Range0.6100 - 4.0900
Volume193,818
Avg. Volume98,941
Market Cap13.085M
Beta (3Y Monthly)3.54
PE Ratio (TTM)N/A
EPS (TTM)-5.6820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2013-06-28
1y Target Est6.50
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition

    VANCOUVER, British Columbia, July 16, 2019 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for.

  • GlobeNewswire19 days ago

    Novelion Therapeutics Receives Delisting Notifications

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, announced that on July 3, 2019, the Company received a written notice from the Nasdaq Stock Market (“Nasdaq”) indicating that it is not in compliance with the requirement for continued listing on the Nasdaq Global Select Market to maintain a minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000, as set forth in Nasdaq Listing Rule 5450(b)(3)(C). Also on July 3, 2019, the Company received a second written notice from Nasdaq indicating that the Company is not in compliance with the requirement for continued listing on the Nasdaq Global Select Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Notice”).

  • GlobeNewswirelast month

    Novelion Therapeutics Responds to Whitefort Capital Petition

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on June 20, 2019, Whitefort Capital Master Fund, LP (“Whitefort”) filed a petition (the “Whitefort Action”) against Novelion Therapeutics Inc. (“Novelion”), as respondent, in the Supreme Court of British Columbia seeking a declaration that Novelion has breached section 301 of the Business Corporations Act of British Columbia (“Section 301 of the BCA”). The petition also includes an order pursuant to Section 301 of the BCA requiring Novelion to hold a special meeting of its shareholders to vote on whether Novelion should “dispose of” the intercompany loan between Novelion (as lender) and Aegerion Pharmaceuticals, Inc. (“Aegerion”) (as debtor) (the “Intercompany Loan”) pursuant to the terms of a Restructuring Support Agreement entered into by, inter alia, Novelion and Aegerion on May 20, 2019 in connection with Aegerion’s Chapter 11 plan of reorganization (the “Plan of Reorganization”) in the United States Bankruptcy Court, Southern District of New York (the “Bankruptcy Court”) Case No. 19-11632 (the “Aegerion Bankruptcy Case”).

  • Benzingalast month

    The 5 Most Expensive Drugs In US: What You Should Know

    The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers. Prices of drugs are staggeringly high in the U.S. when compared to other developed countries such as Japan and in Europe. House lawmakers are discussing a plan that could work to curb high drug prices.

  • Can We See Significant Institutional Ownership On The Novelion Therapeutics Inc. (NASDAQ:NVLN) Share Register?
    Simply Wall St.last month

    Can We See Significant Institutional Ownership On The Novelion Therapeutics Inc. (NASDAQ:NVLN) Share Register?

    The big shareholder groups in Novelion Therapeutics Inc. (NASDAQ:NVLN) have power over the company. Generally...

  • Reuters2 months ago

    UK's Amryt Pharma unites lomitapide franchise with Aegerion deal

    Britain's Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder. Amryt, which already had a licence to sell lomitapide in Europe and countries including Russia, said it would raise $60 million in equity funding for the deal, which will create a group with combined proforma 2018 revenue of $136.5 million.

  • GlobeNewswire2 months ago

    Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion

    Novelion Therapeutics Inc. (NVLN) (Novelion), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that its wholly-owned subsidiary Aegerion Pharmaceuticals, Inc. (Aegerion) has entered into a plan funding agreement (PFA) and a restructuring support agreement (RSA) that will result in Aegerion selling 100% of its reorganized stock to, and becoming a wholly-owned subsidiary of, Dublin-based Amryt Pharma Plc (Amryt). The agreements, which will result in a recapitalization of Aegerion (the Recapitalization), are the result of the previously announced capital structure and strategic review undertaken independently by the Boards of Directors of Novelion and Aegerion, and a broad marketing process.

  • Associated Press3 months ago

    Novelion Therapeutics: 1Q Earnings Snapshot

    The Vancouver, British Columbia-based company said it had a loss of $1.67 per share. Earnings, adjusted for non-recurring costs and stock option expense, were 10 cents per share. The retinal disease treatment ...

  • GlobeNewswire3 months ago

    Novelion Therapeutics Reports First Quarter 2019 Financial Results

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for the first quarter ended March 31, 2019. Growth in JUXTAPID revenue in the first quarter of 2019 compared to the same period in 2018 was due to an increase in revenues in the U.S., primarily resulting from a price increase, and a greater number of patients on therapy in Japan.

  • GlobeNewswire4 months ago

    Novelion Therapeutics Observes World Lipodystrophy Day

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, in association with its subsidiary Aegerion Pharmaceuticals, today announced its observance of World Lipodystrophy Day. World Lipodystrophy Day is an international campaign designed to raise awareness about the impact of living with lipodystrophy. Interim Chief Executive Officer Ben Harshbarger said, "We stand with the patient community in honor of World Lipodystrophy Day with a mission of increasing awareness and diagnosis of this serious rare disease.

  • GuruFocus.com4 months ago

    Novelion Therapeutics Inc (NVLN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Novelion Therapeutics Inc is a biopharmaceutical company. Novelion Therapeutics Inc had annual average EBITDA growth of 2.50% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with NVLN.

  • Associated Press4 months ago

    Novelion Therapeutics: 4Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.03. Earnings, adjusted for non-recurring costs and stock option expense, were 15 cents per share. The retinal ...

  • GlobeNewswire4 months ago

    Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

    Company achieves FY 2018 total net revenues of $130.4 million FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and CAMBRIDGE, Mass.,.

  • GlobeNewswire5 months ago

    Novelion Therapeutics Observes Rare Disease Day

    VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2019 -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards.

  • ACCESSWIRE5 months ago

    Biotech Stocks Set to Pop

    HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...

  • GlobeNewswire6 months ago

    Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that its subsidiary, Aegerion Pharmaceuticals, Inc. (“Aegerion”), has entered into an exclusive licensing agreement with Recordati Rare Diseases Inc. (“Recordati”) for the commercialization of JUXTAPID® (lomitapide) in Japan. The agreement includes exclusive rights in Japan for Recordati to commercialize JUXTAPID for the current approved indication, homozygous familial hypercholesterolemia (HoFH), and Aegerion grants Recordati an exclusive right of first negotiation for product commercialization in Japan of any potential new indications that may be developed by Aegerion.

  • 5 Top Rising P/E Stocks to Enjoy Solid Gains
    Zacks7 months ago

    5 Top Rising P/E Stocks to Enjoy Solid Gains

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • ACCESSWIRE8 months ago

    Today's Research Reports on Trending Tickers: Novelion Therapeutics and Revance Therapeutics

    NEW YORK, NY / ACCESSWIRE / December 5, 2018 / Shares of Novelion Therapeutics and Revance Therapeutics were both soaring on Tuesday on separate developments. Novelion saw gains as it was revealed that biotech focused venture capital firm Healthcare Value Capital sent a letter demanding exploration of strategic alternatives, while Revance Therapeutics soared on news that its Botox rival succeeds in late-stage trial and that it had reached an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Novelion Therapeutics Inc. shares were up 32.65% yesterday at the close on almost 17.5 million shares traded.

  • Benzinga8 months ago

    Novelion Rises 50% After Activist Investor Demands Exploration Of Strategic Alternatives

    Novelion revealed through an amendment to a SEC 13-D filing that biotech-focused venture capital firm Healthcare Value Capital sent a letter to Novelion's board urging the exploration of strategic alternatives. In the letter signed by Joseph Riccardo, managing member at Healthcare Value Capital, the firm accused Novelion of allowing costs to spiral out of control.

  • ACCESSWIRE8 months ago

    Today's Research Reports on Trending Tickers: Novelion Therapeutics and ReShape Lifesciences

    ReShape announced several encouraging developments including data regarding the treatment of type 2 diabetes mellitus but saw its shares sold off. Novelion Therapeutics Inc. shares were up 7.61% at the close yesterday with roughly 2% more seen in after-hours trading in gains. There was no significant news from the company yesterday but it was last week that the biopharmaceutical company said that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D., effective immediately.

  • ACCESSWIRE8 months ago

    New Healthcare Trends Could Push Sector Stocks Higher

    CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.

  • Benzinga8 months ago

    The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...

  • GlobeNewswire8 months ago

    Novelion Therapeutics Announces Leadership Change

    Novelion Therapeutics Inc. (NVLN), today announced that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D., effective immediately. Jeffrey Hackman resigned as interim CEO to pursue another opportunity and will stay with the Company in a transitional role until November 30, 2018. Dr. Corrigan commented, “In the past year, we have made substantial progress in the turnaround of Novelion, and on behalf of the Board of Directors, I’d like to thank Jeff for his dedication to this mission.

  • GlobeNewswire8 months ago

    Novelion Therapeutics Reports Third Quarter 2018 Financial Results

    VANCOUVER, British Columbia, Nov. 09, 2018 -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Perrigo Company and Novelion Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 9, 2018 / While shares of healthcare company Perrigo Company were tanking after reporting third quarter financial results, Novelion Therapeutics, which is developing ...